# EDGAR Filing Document

**Accession Number:** 0001176309
**File Stem:** 0001213900-26-069783
**Filing Date:** 2026-6
**Character Count:** 11260
**Document Hash:** 6fa1508a0ff5a2db1bb97af3804cdae9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-069783.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001213900-26-069783

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nano Dimension Ltd.
- **CENTRAL INDEX KEY:** 0001643303
- **STANDARD INDUSTRIAL CLASSIFICATION:** PRINTED CIRCUIT BOARDS [3672]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 520029109
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89872
- **FILM NUMBER:** 261100148

**BUSINESS ADDRESS:**
- **STREET 1:** 60 TOWER ROAD,
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 972 54 6244465

**MAIL ADDRESS:**
- **STREET 1:** 60 TOWER ROAD,
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORAMED PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001176309
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980376008
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 646-844-1164

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integrated Security Technologies, Inc.
- **DATE OF NAME CHANGE:** 20040614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IGUANA VENTURES LTD
- **DATE OF NAME CHANGE:** 20020625

## Exhibit 99.1

**Exhibit 99.1**

**ANNEX A**

**RECENT TRANSACTIONS BY THE REPORTING PERSONS IN THE SECURITIES OF Nano Dimension Ltd.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Entity** | **Date of Transaction** | **Description** <br> **of Transaction** | **Shares Acquired** | **Shares** <br> **Disposed** | **Price** <br> **Per Share** |
| Oramed Pharmaceuticals Inc. | &nbsp;&nbsp;5/13/2026 | &nbsp;&nbsp;Open Market Purchase | 716539 |  | $1.73 |
| Oramed Pharmaceuticals Inc. | &nbsp;&nbsp;5/14/2026 | &nbsp;&nbsp;Open Market Purchase | 620026 |  | $1.69 |
| Oramed Pharmaceuticals Inc. | &nbsp;&nbsp;5/14/2026 | &nbsp;&nbsp;Open Market Sale |  | 600 | $2.00 |
| Oramed Pharmaceuticals Inc. | &nbsp;&nbsp;6/15/2026 | &nbsp;&nbsp;Open Market Purchase | 5000000 |  | $1.27 |
| Oramed Pharmaceuticals Inc. | &nbsp;&nbsp;6/15/2026 | &nbsp;&nbsp;Open Market Sale |  | 500000 | $1.27 |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Nano Dimension Ltd.**

*(Name of Issuer)*

**Ordinary Shares, par value NIS 5.00 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Avraham Gabay**<br>1185 Avenue of the Americas, Third Floor<br>New York NY 10036<br>972 25788763

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/15/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Oramed Pharmaceuticals Inc.** | Name of reporting person<br>**Oramed Pharmaceuticals Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**15079708.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**15079708.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**15079708.00** | Aggregate amount beneficially owned by each reporting person<br>**15079708.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.2%** | Percent of class represented by amount in Row (11)<br>**7.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value NIS 5.00 per share

**(b) Name of Issuer:**
Nano Dimension Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
60 TOWER ROAD, WALTHAM, MA, 02451

This Amendment No. 2 to Schedule 13D is filed by and on behalf of the Reporting Person to further amend the Schedule 13D related to the Ordinary Shares, par value NIS 5.00 per share (the "Ordinary Shares") of Nano Dimension Ltd. (the "Issuer"), initially filed with the U.S. Securities and Exchange Commission on January 29, 2026, as amended by Amendment No. 1 to Schedule 13D that was filed by the Reporting Person with the SEC on February 19, 2026 (as amended, the "Schedule 13D").  Each capitalized term used and not defined herein shall have the meaning assigned to such term in the Schedule 13D. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.

**Item 4. Purpose of Transaction**

Item 4 is hereby amended and supplemented as follows:

"On June 15, 2026, the Issuer issued a press release announcing the signing of a term sheet with Infinite Epigenetics to form a publicly traded, AI-powered preventive health and diagnostics company (the "Proposed Transaction"). While the Reporting Person is evaluating all options available to it with respect to the Proposed Transaction, as an initial matter, the Reporting Person believes the Proposed Transaction is not in the best interests of the Issuer's shareholders and is strongly opposed to it."

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) is hereby amended and restated in its entirety as follows:

"(a) The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is stated in Items 11 and 13 on the cover pages hereto.

The percentage reported in Item 13 on the cover pages hereto is based upon 210,354,507 Ordinary Shares of the Issuer outstanding as of May 27, 2026, according to the Schedule 14A filed by the Issuer with the U.S. Securities and Exchange Commission (the "SEC") on June 5, 2026."

**(b)**
Item 5(b) is hereby amended and restated in its entirety as follows:

"Number of shares as to which the Reporting Person has

(i) sole power to vote or direct the vote: See Item 7 on the cover page(s) hereto.

(ii) shared power to vote or direct the vote

     See Item 8 on the cover page(s) hereto.

(iii) sole power to dispose or to direct the disposition of:

     See Item 9 on the cover page(s) hereto.

(iv) shared power to dispose or to direct the disposition of:

     See Item 10 on the cover page(s) hereto."

**(c)**
Item 5(c) is hereby amended and restated in its entirety as follows:

"(c) Other than as set forth in Item 3, Item 6, and on Annex A of this Schedule 13D, there have been no transactions in the class of securities reported on that were effected by the Reporting Person during the past sixty days or since the most recent filing of Schedule 13D, whichever is less."

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby amended and supplemented as follows:

"The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference.

On May 14, 2026, the Reporting Person engaged in the following transactions: (i) sold call options for an aggregate of approximately $702,985 (excluding commissions) referencing an aggregate of 3,700,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share and expiring on November 20, 2026; (ii) purchased call options referencing an aggregate of 3,700,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share and expiring on May 15, 2026; (iii) purchased put options referencing an aggregate of 3,700,000 Ordinary Shares, having an exercise price of $1.50 per Ordinary Share and expiring on August 21, 2026; and (iv) sold put options for an aggregate of approximately $1,109,977 (excluding commissions) referencing an aggregate of 3,700,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share and expiring on May 15, 2026.

On May 18, 2026, the Reporting Person exercised put options referencing an aggregate of 1,325,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share, resulting in the sale of 1,325,000 Ordinary Shares.

On June 15, 2026, the Reporting Person engaged in the following transactions: (i) sold call options for an aggregate of approximately $699,985 (excluding commissions) referencing an aggregate of 3,500,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share and expiring on November 20, 2026, and purchased call options referencing an aggregate of 350,000 Ordinary Shares, having the same exercise price and expiration; (ii) sold call options for an aggregate of approximately $63,748 (excluding commissions)  referencing an aggregate of 1,500,000 Ordinary Shares, having an exercise price of $1.50 per Ordinary Share and expiring on August 21, 2026, and purchased call options referencing an aggregate of 150,000 Ordinary Shares, having the same exercise price and expiration; and (iii) purchased put options referencing an aggregate of 5,000,000 Ordinary Shares, having an exercise price of $1.00 per Ordinary Share and expiring on August 21, 2026, and sold put options for an aggregate of approximately $44,999 (excluding commissions) referencing an aggregate of 500,000 Ordinary Shares, having the same exercise price and expiration."

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Oramed Pharmaceuticals Inc.

**Signature:** /s/ Avraham Gabay

**Name/Title:** Avraham Gabay, Chief Financial Officer

**Date:** 06/17/2026